Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity
about
Beyond THC: The New Generation of Cannabinoid Designer DrugsNeuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like StimulantsSpice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoidsAM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studiesDistinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in MiceNovel Drugs of Abuse: A Snapshot of an Evolving Marketplace.The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products."Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects.Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice.Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS.Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice.Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS.1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in miceThe synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse.Baths salts, spice, and related designer drugs: the science behind the headlines.Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens.JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeysMonohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.Validation of an ELISA Synthetic Cannabinoids Urine AssayApparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeysAssessment of the Abuse Liability of Synthetic Cannabinoid Agonists JWH-030, JWH-175, and JWH-176.Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific maInhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in miceGas chromatography-mass spectrometry of JWH-018 metabolites in urine samples with direct comparison to analytical standardsHuman metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry.(-)-Trans-Δ(9)-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis UsersSpicing things up: synthetic cannabinoids.Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparationsRegioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions.Characterization of Structurally Novel G Protein Biased CB1 Agonists: Implications for Drug Development.Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA.
P2860
Q24635230-EE817CA4-9129-460D-9B57-0013A359E80DQ26752739-56C0A0F9-F750-4970-AC5A-FE9DF4F4584DQ27010555-B6EEF690-B5C6-452D-B8B7-B4698787878DQ28270589-9BCB68D5-A730-4EF9-BE96-B488B98A2402Q28540537-81707A9C-F279-447D-8B2D-3A5E83A47EC3Q33583810-B940E58B-FFFD-45E8-95FB-8EAA665A34CBQ33725088-C06ED159-2FFC-4C50-A89A-AAB768810A38Q33908169-154C2679-BFAF-4CB3-A649-B25973BB7275Q34055910-D71324D3-EFC8-4645-93AF-8DBBBA6F17F6Q34098379-A3C932C5-7050-4C8E-92DF-EF2F7FBC3417Q34133537-0213FECA-DF4F-4F2B-8426-A88DF2EEA823Q34142699-31972DD2-D127-453E-A945-74EABBEBDA09Q34148141-7E974478-B964-4E1C-A329-10F826800B7EQ34156299-C0680E97-8E83-4393-AFC6-9DE5A2578ACBQ34236794-D8F0834A-5F2C-41DB-B6FA-12F9DE49EA37Q34336690-ADB56187-C2B1-431F-AEF4-5962B9F854CAQ34491601-C20885EF-2BAF-475C-A0ED-D099ED4DF84AQ34617484-4F0917BA-FD71-4453-8565-987D51520D8EQ35172366-8C1E7141-9DC8-44FE-B53F-6B83194CE137Q35187100-D4D4B576-6D47-4A6D-8A04-2A43CFD56B98Q35650744-91B46BFB-8A70-4A4B-93A6-2AED4D5A87ACQ35785005-90B37316-51B7-48BD-B96E-1BCB722134AFQ35981647-440572DF-665D-4319-8135-B701AF3BD3A5Q36174226-F5DF113A-8075-409C-A3E5-9853EDDC9766Q36218416-72643FA3-6734-42C3-A02F-E9CAA57F07B9Q36335446-E13B3A0E-0EF5-4449-ACEB-07772B71B6F7Q36385137-146027E2-7EE2-4D88-BCC3-6FCBBB4F8DAEQ36409544-09096638-1DFD-4BD2-8F2A-EDE12A79A777Q36865579-28BBA0B4-7897-4795-A11D-78F15FDD6564Q36938493-AC99C392-243D-4D50-8978-FA1932BF517EQ36950560-4C58ED6D-99D6-4712-A249-A076CED307D9Q37058566-64860C8B-40E8-4430-920B-964A3F60A1AAQ37237996-5EB4BE46-C59F-4733-BAF6-B0459E263AA3Q37575719-81366F5E-6712-4ADD-A4D1-D9793D1090AEQ37578979-E8CF5664-7707-4F4F-9248-02FFDA8F92C0Q37648995-A11A52CE-AF1A-4955-9B6F-07079E88852BQ38008438-0741A409-DC81-4755-818F-8FA7FA30CF6CQ38429080-6B52A792-E3E6-431D-8B99-6D3F5C33216AQ38611708-DAFB43A4-D659-4221-ABC0-CB7A1E6DCA42Q38616637-FBB19519-B5B1-4839-91F8-2819E1DE70F7
P2860
Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I hydroxylated metabolit ...... receptor affinity and activity
@ast
Phase I hydroxylated metabolit ...... receptor affinity and activity
@en
Phase I hydroxylated metabolit ...... receptor affinity and activity
@en-gb
Phase I hydroxylated metabolit ...... receptor affinity and activity
@nl
type
label
Phase I hydroxylated metabolit ...... receptor affinity and activity
@ast
Phase I hydroxylated metabolit ...... receptor affinity and activity
@en
Phase I hydroxylated metabolit ...... receptor affinity and activity
@en-gb
Phase I hydroxylated metabolit ...... receptor affinity and activity
@nl
prefLabel
Phase I hydroxylated metabolit ...... receptor affinity and activity
@ast
Phase I hydroxylated metabolit ...... receptor affinity and activity
@en
Phase I hydroxylated metabolit ...... receptor affinity and activity
@en-gb
Phase I hydroxylated metabolit ...... receptor affinity and activity
@nl
P2093
P2860
P921
P3181
P1433
P1476
Phase I hydroxylated metabolit ...... receptor affinity and activity
@en
P2093
Emily E Reichard
Jeffery H Moran
Lisa K Brents
Paul L Prather
Sarah M Zimmerman
William E Fantegrossi
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0021917
P407
P577
2011-01-01T00:00:00Z